Pneumagen Company

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Technology: Anti-infective Drugs
Industry: Gene therapy
Headquarters: Saint Andrews, Fife, United Kingdom
Founded Date: 2016
Employees Number: 1-10
Investors Number: 2
Total Funding: £4M
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown

Visit Website
info@pneumagen.com
Register and Claim Ownership